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Pyrimidine derivative 3 was afforded through the reaction of compound (1) with 5-ureidohydantion (2). 
Product 3 underwent a cyclization to produce fused pyrimidine derivative 7, although the latter product 
7 was synthesized through one step via the reaction of compound (1) with 5-ureidohydantion (2) using 
another catalyst. Compound 3 was oriented to react with cyclic ketones 8a,b in the presence of elemental 
sulfur, salicylaldehyde (10), aryldiazonium chlorides 12a,b and ω-bromo-4-methoxy- acetophenone 
(14), which afforded, fused thiophene derivatives 9a,b, coumarin derivative 11, arylhdrazono derivatives 
13a,b and 4-methoxyphenyl butenyl derivative 15, respectively. The latter product 15 was reacted with 
either potassium cyanide (16a) or potassium thiocyanide (16b) to form cyano and thiocyano derivatives 
17a,b, respectively. Compound 17a underwent further cyclization to afford pyridopyrimidine derivative 
19. Compound 15 was reacted with either hydrazine (20a) or phenylhydrazine (20b) to produce hydrazo 
derivatives 21a,b and these products were cyclize to produce pyrrole derivatives 23a,b. Finally, 
5-ureidohydantion (2) was reacted with compounds 24a,b,c to afford pyrimidine derivatives 25a,b,c. 
The structures of the synthesized compounds were confirmed using IR, 1H NMR, 13C NMR and mass 
spectrometry techniques. Compounds 11 and 19 have promising as analgesic and antipyretic activities.
Keywords: Pyrimidine derivative. Thiophene. Coumarin. Pyridine. Pyrrole. Analgesic. Antipyretic and 
anti-inflammatory agents. 
INTRODUCTION
A series of studies was introduced to discover 
that hydantoin derivatives, important heterocyclic 
compounds, act as antioxidant agents (Gus’kov et al., 
2004). Moreover, Imidazolidine-2,4 dione derivatives are 
specific biologically active compounds and act as anti-
proliferative agents (Reddy et al., 2010), hypoglycemic, 
aldose reductase inhibitor agents (Iqbal et al., 2015) and 
Bcl-2 inhibitors (Wang et al., 2015). 
Pyridopyrimidine derivatives have a wide variety of 
biological properties, including antileishmanial (Agarwal 
et al., 2005) and antitubercular activities (Horvati et al., 
2015; Rajesh et al., 2011). Additionally fused thiophene 
derivatives have antitumor activity (Dallemagne et al., 
2003) and pyrimidine derivatives containing the coumarin 
moiety have analgesic and anti-pyretic effects (Keri et 
al., 2010). Hydrazono derivatives have shown anticancer 
activity (Sztanke, Rzymowska, Sztanke, 2013) and pyrrole 
derivatives have antibacterial activity (Padmavathi et al., 
2011). In this article we aimed to improve and discover 
the analgesic, antipyretic and anti-inflammatory activities 
of synthesized compounds.
MATERIAL AND METHODS
General procedures
The melting points of the synthesized compounds 
were determined in open capillaries and are uncorrected. 
Elemental analyses were performed on a Yanaco CHNS 
Corder elemental analyzer (Japan). IR spectra were 
measured using KBr discs on a Pye Unicam SP-1000 
spectrophotometer. 1H NMR and 13C NMR spectra were 
measured on a Varian EM 390-200 MHz instrument 
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with CD3SOCD3 as the solvent using TMS as an internal 
standard material, the chemical shifts were expressed as δ 
ppm. Mass spectra were recorded on Kratos (75 eV) MS 
equipment (Germany). 
General procedures for the synthesis of compound: 
3-(4,6-diamino-1-(2,5-dioxoimidazolidin-4-yl)-2-oxo-1,2-
dihydropyrimidin-5-yl)-3-iminopropanenitrile (3)
β-amino-α,γ-dicyanocrotononitrile (1) (3.96 g, 
0.03 mol) was added to a 5-ureidohydantoin solution 
(2) (4.743 g, 0.03 mol) in 100 mL of ethanol containing 
dimethylformamide (5mL) and triethylamine (1.0 mL) as 
a catalyst. The reaction mixture was heated under reflux 
for 6 h, cooled and poured onto ice containing a few drops 
of HCl. Then, the formed solid product was filtered out.
Compound 3: Faint yellow crystals from ethanol, 
yield 54%, 4.701 g, m.p. 168-170 ºC. IR (KBr): υ/cm-1 = 
3438-3355 (2NH2, 3NH), 2883 (CH2), 2765 (CH), 2223 
(CN), 1673, 1668, 1661 (3CO), 1648 (C=C). 1H NMR 
(DMSO-d6) δ = 3.05-3.13 (s, 2H, CH2), 4.87, 5.12 (2s, 4H, 
D2O-exchangeable, 2NH2), 5.74 (s, 1H, imidazolidindione 
ring), 8.35, 9.22, 9.79 (3s, 3H, D2O-exchangeable, 3NH). 
13C NMR: δ = 40.9 (CH2), 62.1 (CH), 106.4 (C=NH), 
116.9 (CN), 120.1, 148.6, 152.7 (pyrimidine C), 164.4, 
168.3, 171.7 (3C=O). MS (relative intensity) m/z: 290 
(M+, 32.2%). Calcd for C10H10N8O3 (290.24): C, 41.38; 
H, 3.47; N, 38.61%. Found: C, 41.65; H, 3.24; N, 38.90%.
General procedure for the synthesis of compound: 
5-(4,5,7-triamino-2-oxopyrido-[2,3-d]pyrimidin-3(2H)-yl)
imidazolidine-2,4-dione (7)
Method (A): A solution of compound 3 (0.58 g, 
0.002 mol) in ethanol (50 mL) containing a catalytic 
amount of piperidine (0.5 mL) was heated under reflux 
for 5 h, poured onto an ice/water mixture containing a few 
drops of hydrochloric acid. The formed solid product was 
collected by filtration.
Method (B): β-Amino-α, γ-dicyanocrotononitrile (1) 
(0.396 g, 0.003 mol) was added to a solution of compound 
2 (0.474 g, 0.003 mol) in sodium ethoxide (0.003 mol) 
[prepared by dissolving sodium metal (0.069 g, 0.003 
mol) in absolute ethanol (50 mL)]. The reaction mixture 
was heated under reflux for 6 h and then evaporated under 
vacuum. The product was triturated with ethanol and the 
formed solid product was collected by filtration.
Compound 7: Brown crystals from ethanol, yield 
66%, 0.575 g, m.p. 115-117 ºC. IR (KBr): υ/cm-1 = 
3488-3327 (3NH2, 2NH), 2783 (CH), 1695, 1684, 1662 
(3CO), 1651 (C=N). 1H NMR (DMSO-d6) δ = 4.78, 
4.93, 5.27 (3s, 6H, D2O-exchangeable, 3NH2), 5.67 (s, 
1H, imidazolidindione ring), 6.87 (s, 1H, pyridine ring), 
8.73, 9.95 (2s, 2H, D2O-exchangeable, 2NH). 13C NMR: 
δ = 55.7 (CH), 124.3, 133.4, 138.5, 144.7, 150.3, 152.4 
(pyridine C, pyrimidine C), 166.1, 169.7, 173.2 (3C=O). 
Calcd for C10H10N8O3 (290.24): C, 41.38; H, 3.47; N, 
38.61%. Found: C, 41.11; H, 3.73; N, 38.99%.
General procedure for the synthesis of compounds: 
5 - (4 ,6-d iamino-5- ( (2-amino-5,6-d ihydro-4H-
cyclopenta[b]thiophen-3-yl)(imino)methyl)-2-oxo-
pyrimidin-1(2H)-yl) imidazolidine-2,4-dione (9a) and 
5-(4,6-diamino-5-((2-amino-4,5,6,7-tetrahydrobenzo 
[b]thiophen-3-yl(imino) methyl)-2-oxopyrimidin-1(2H) 
yl) imidazolidine-2,4-dione (9b)
To a solution of compound 3 (0.58 g, 0.002 mol) in 
ethanol (50 mL) containing trimethylamine (0.5 mL), either 
cyclopentanone (8a) (0.168 g, 0.002 mol) or cyclohexanone 
(8b) (0.196 g, 0.002 mol) together with elemental sulfur 
(0.064 g, 0.002 mol) were added. The reaction mixture was 
heated under reflux for 4 h, cooled and poured onto an ice/
water mixture containing a few drops of HCl. The formed 
precipitate was collected by filtration.
Compound 9a: Brown crystals from 1,4-dioxane, 
yield 63%, 0.489 g, m.p. 202-204 ºC. IR (KBr): υ/cm-1 = 
3458-3336 (3NH2, 3NH), 2880 (CH2), 2796 (CH), 1683, 
1674, 1663 (3CO), 1653 (C=N), 1646 (C=C), 684 (C-S). 
1H NMR (DMSO-d6) δ = 2.07-2.18 (m, 6H, 3CH2), 4.54, 
4.65, 5.81 (3s, 6H, D2O-exchangeable, 3NH2), 5.98 (s, 1H, 
imidazolidindione ring), 8.52, 8.77, 9.12 (3s, 3H, D2O-
exchangeable, 3NH). 13C NMR: δ = 22.4, 27.3, 29.9 (3 
CH2), 51.3 (CH), 93.8 (C=NH), 126.2, 131.5, 136.3, 140.5, 
142.7, 149.1, 151.6 (thiophene C, pyrimidine C), 165.4, 
168.8, 172.1 (3C=O). Calcd for C15H16N8O3S (388.40): C, 
46.38; H, 4.15; N, 28.85; S, 8.26%. Found: C, 46.17; H, 
3.89; N, 28.66; S, 8.01%.
Compound 9b: Brown crystals from 1,4-dioxane, 
yield 58%, 0.477 g, m.p. 212-214 ºC. IR (KBr): υ/cm-1 = 
3460-3349 (3NH2, 3NH), 2882 (CH2), 2768 (CH), 1677, 
1671, 1664 (3CO), 1655 (C=N), 1649 (C=C), 676 (C-S). 
1H NMR (DMSO-d6) δ = 2.18-2.39 (m, 8H, 4CH2), 4.48, 
4.69, 5.45 (3s, 6H, D2O-exchangeable, 3NH2), 5.86 (s, 1H, 
imidazolidindione ring), 8.61, 8.86, 9.08 (3s, 3H, D2O-
exchangeable, 3NH). 13C NMR: δ = 22.8, 25.4, 27.3, 29.6 
(4 CH2), 54.7 (CH), 97.1 (C=NH), 128.1, 134.7, 138.6, 
141.5, 146.6, 150.8, 153.3 (thiophene C, pyrimidine 
C), 162.2, 166.7, 170.6 (3C=O). Calcd for C16H18N8O3S 
(402.43): C, 47.75; H, 4.51; N, 27.84; S, 7.97%. Found: 
C, 47.56; H, 4.78; N, 28.09; S, 7.68%.
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General procedure for the synthesis of compound:- 
5-(4,6-diamino-5-(imino(2-oxo-2H-chromen-3-yl)
methyl)-2-oxopyrimidin-1(2H)-yl)imidazolidine-2,4-dione 
(11)
Salicylaldehyde (10) (0.244 g, 0.002 mol) was 
added to a solution of compound 3 (0.58 g, 0.002 mol) in 
1,4-dioxane (50 mL) containing piperidine (0.5 mL). The 
reaction mixture was heated under reflux for 5 h and then 
evaporated under vacuum. The solid product was triturated 
with ethanol and the formed solid product was collected 
by filtration.
Compound 11: Yellowish brown crystals from 
1,4-dioxane, yield 70%, 0.553 g, m.p. 185-187 ºC. 
IR (KBr): υ/cm -1 = 3443-3311 (2NH2, 3NH), 3052 
(CH-aromatic.), 2762 (CH), 1835, 1681, 1666, 1660 
(4C=O), 1652 (C=N), 1112 (CO), 1649 (C=C). 1H NMR 
(DMSO-d6) δ = 4.76, 5.25 (2s, 4H, D2O-exchangeable, 
2NH2), 5.53 (s, 1H, imidazolidindione ring), 6.73 (s, 1H, 
coumarin H-4), 7.51- 7.66 (m, 4H, C6H4), 8.88, 9.28, 9.55 
(3s, 3H, D2O-exchangeable, 3NH). 13C NMR: δ = 59.5 
(CH), 95.3 (C=NH), 125.5, 131.9, 136.8, 140.7, 144.5, 
147.2, 149.1, 151.3, 153.5 (pyrimidine C, coumarin C), 
161.5, 165.8, 170.3, 181.5 (4C=O). Calcd for C17H13N7O5 
(395.33): C, 51.65; H, 3.31; N, 24.80%. Found: C, 51.93; 
H, 3.59; N, 24.55%.
General procedure for the synthesis of compounds:- 
2-(4,6-diamino-1-(2,5-dioxo- imidazolidin-4-yl)-2-
oxo1,2-dihydropyrimidin-5-yl)-2-imino-N’-phenyl-
acetohydrazonoyl cyanide (13a) and N’-(4-chlorophenyl)-
2-(4,6-diamino-1-(2,5-dioxo- imidazolidin-4-yl-2-oxo-
1,2-dihydropyrimidin-5-yl)-2-iminoaceto-hydrazonoyl 
cyanide (13b)
To a cold solution (0-5 °C) of pyrimidine derivative 3 
(0.58 g, 0.002 mol) in ethanol (50 mL) containing sodium 
acetate (0.164 g, 0.002 mol) either benzenediazonium 
chloride (12a) or 4-chlorobenzenediazonium chloride 
(12b) (0.002 mol) [prepared by adding an aqueous sodium 
nitrite solution (0.138 g, 0.002 mol) to a cold solution 
of either aniline or 4-chloroaniline (0.002 mol) in the 
appropriate amount of glacial acetic acid at (0-5 °C) with 
continuous stirring] was added with continuous stirring. 
The reaction mixture was stirred at room temperature for 
an additional 4 h and the solid product was collected by 
filtration.
Compound 13a: Pale brown crystals from ethanol, 
yield 67%, 0.528 g, m.p. 137- 139 ºC. IR (KBr): 
υ/cm-1 = 3476-3354 (2NH2, 4NH), 3053 (CH aromatic), 
2761 (CH), 2223 (CN), 1678, 1667, 1663 (3CO), 1657 
(C=N), 1646 (C=C). 1H NMR (DMSO-d6) δ = 4.54, 
5.17 (2s, 4H, D2O-exchangeable, 2NH2), 5.61 (s, 1H, 
imidazolidindione ring), 7.31- 7.62 (m, 5H, C6H5), 8.76, 
9.13, 9.38, 9.59 (4s, 4H, D2O-exchangeable, 4NH). 
13C NMR: δ = 67.3 (CH), 92.4, 109.2 (2C=N), 120.4 
(CN), 123.3, 125.9, 127.9, 130.4, 132.8, 134.6, 138.4, 
142.5 (pyrimidine C, C6H5), 163.9, 166.8, 169.3 (3C=O). 
MS (relative intensity) m/z: 394 (M+, 17.9%). Calcd for 
C16H14N10O3 (394.35): C, 48.73; H, 3.58; N, 35.52%. 
Found: C, 48.48; H, 3.29; N, 35.80%.
Compound 13b: Dark brown crystals from ethanol, 
yield 61%, 0.523 g, m.p. 193-195 ºC. IR (KBr): υ/cm-1 
= 3451-3290 (2NH2, 4NH), 3050 (CH aromatic), 2770 
(CH), 2224 (CN), 1673, 1663, 1659 (3CO), 1652 (C=N), 
1647 (C=C). 1H NMR (DMSO-d6) δ = 4.63, 5.08 (2s, 4H, 
D2O-exchangeable, 2NH2), 5.89 (s, 1H, imidazolidindione 
ring), 7.44- 7.58 (d.d, 4H, C6H4), 8.58, 9.24, 9.55, 9.67 (4s, 
4H, D2O-exchangeable, 4NH). 13C NMR: δ = 62.5 (CH), 
98.4, 106.4 (2C=N), 121.7 (CN), 122.5, 124.8, 125.8, 128.3, 
131.6, 135.3, 137.7, 141.5 (pyrimidine C, C6H5), 162.8, 
165.7, 168.8 (3C=O). MS (relative intensity) m/z: 428 
(M+, 23.4%). Calcd for C16H13ClN10O3 (428.79): C, 44.82; 
H, 3.06; N, 32.67%. Found: C, 44.56; H, 3.33; N, 32.40%.
General procedure for synthesis of compound: 4-bromo-
2-((4,6-diamino-1-(2,5-dioxo- imidazolidin-4-yl)-2-oxo-
1,2-dihydropyrimidin-5-yl) (imino) methyl)-3-(4-methoxy- 
phenyl) but-2-enenitrile (15)
ω-Bromo-4-methoxyacetophenone (14) (0.524 g, 
0.002 mol) was added to a solution of compound 3 (0.58 g, 
0.002 mol) in 1,4-dioxane (40 mL). The reaction mixture 
was stirred at room temperature for 2 h and then poured 
on to a beaker containing ice/water mixture. The formed 
solid product was collected by filtration.
Compound 15: Brown crystals from ethanol, yield 
72%, 0.712 g, m.p. 121-123 ºC. IR (KBr): υ/cm-1 = 3422-
3286 (2NH2, 3NH), 3055 (CH aromatic), 2986 (CH3), 
2867 (CH2), 2766 (CH), 2225 (CN), 1680, 1669, 1662 
(3CO), 1658 (C=N), 1648 (C=C). 1H NMR (DMSO-d6) δ 
= 3.32 (s, 3H, OCH3), 3.77 (s, 2H, CH2), 4.81, 5.29 (2s, 4H, 
D2O-exchangeable, 2NH2), 5.55 (s, 1H, imidazolidindione 
ring), 7.48-7.71 (d.d, 4H, C6H4), 8.66, 9.22, 9.45 (3s, 3H, 
D2O-exchangeable, 3NH). 13C NMR: δ = 41,2 (CH3), 
49.5 (CH2), 65.3 (CH), 81.3, 88.6 (C=C), 103.7 (C=N), 
118.3 (CN), 124.6, 126.7, 129.3, 131.5, 133.9, 135.4, 
137.8 (pyrimidine C, C6H4), 160.7, 165.7, 169.8 (3C=O). 
MS (relative intensity) m/z: 500 (M+, 13.8%), 502 (M+, 
13.4%), Calcd for C19H17BrN8O4 (501.29): C, 45.52; H, 
3.42; N, 22.35%. Found: C, 45.81; H, 3.19; N, 22.63%.
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General procedure for the synthesis of compounds: 
2-((4,6-diamino-1-(2,5-dioxo- imidazolidin-4-yl)-2-
oxo-1,2-dihydropyrimidin-5-yl) (imino) methyl)-3- 
(4- methoxy-phenyl-pent-2-enedinitrile (17a) and 
2-((4,6-diamino-1-(2,5-dioxo-imidazolidin-4-yl)-2-
oxo-1,2-dihydropyrimidin-5-yl)(imino)methyl)-3-(4-
methoxyphenyl)-4-thio-cyanatobut-2-enenitrile (17b)
Either potassium cyanide (16a) (0.122 g, 0.002 
mol) or potassium thiocyanate (16b) (0.189 g, 0.002 
mol) was added to a solution of compound 15 (1.002 
g, 0.002 mol) in ethanol (50 mL) in water bath at 60 
oC, with continuous stirring. The reaction mixture was 
maintained in the water bath for 1 h at 60 ºC and then 
poured into a beaker containing an ice/water mixture 
and a few drops of HCl. The formed solid product was 
collected by filtration. 
Compound 17a: Dark brown crystals from ethanol, 
yield 69%, 0.617 g, m.p. 157-159 ºC. IR (KBr): υ/cm-1 
= 3445-3266 (2NH2, 3NH), 3051 (CH aromatic), 2978 
(CH3), 2881 (CH2), 2754 (CH), 2225, 2223 (2CN), 1682, 
1673, 1661 (3CO), 1657 (C=N), 1649 (C=C). 1H NMR 
(DMSO-d6) δ = 3.41 (s, 3H, OCH3), 3.76 (s, 2H, CH2), 
4.55, 4.87 (2s, 4H, D2O-exchangeable, 2NH2), 5.63 (s, 
1H, imidazolidindione ring), 7.33-7.54 (d.d, 4H, C6H4), 
8.45, 8.76, 9.33 (3s, 3H, D2O-exchangeable, 3NH). 13C 
NMR: δ = 38.1 (CH3), 48.9 (CH2), 62.7 (CH), 77.7, 83.5 
(C=C), 97.6 (C=N), 116.5, 119.2 (2CN), 122.8, 125.4, 
128.6, 130.6, 134.4, 136.7, 138.9 (pyrimidine C, C6H4), 
161.4, 164.5, 168.1 (3C=O). MS (relative intensity) 
m/z: 447 (M+, 28.4%). Calcd for C20H17N9O4 (447.41): 
C, 53.69; H, 3.83; N, 28.18%. Found: C, 53.96; H, 3.59; 
N, 28.43%.
Compound 17b: Brown crystals from ethanol, 
yield 64%, 0.613 g, m.p. 181-183 ºC. IR (KBr): υ/cm-1 
= 3423-3233 (2NH2, 3NH), 3053 (CH aromatic), 2960 
(CH3), 2884 (CH2), 2760 (CH), 2224, 2221 (2CN), 1680, 
1672, 1662 (3CO), 1659 (C=N), 1651 (C=C). 1H NMR 
(DMSO-d6) δ = 3.25 (s, 3H, OCH3), 3.44 (s, 2H, CH2), 
4.51, 4.73 (2s, 4H, D2O-exchangeable, 2NH2), 5.55 (s, 1H, 
imidazolidindione ring), 7.39- 7.61 (d.d, 4H, C6H4), 8.56, 
8.74, 9.22 (3s, 3H, D2O-exchangeable, 3NH). 13C NMR: 
δ = 41.2 (CH3), 49.7 (CH2), 63.9 (CH), 76.7, 86.8 (C=C), 
97.9 (C=N), 117.2, 119.8 (2CN), 123.9, 126.7, 129.9, 
132.5, 136.2, 138.9, 140.7 (pyrimidine C, C6H4), 162.2, 
164.8, 167.8 (3C=O). MS (relative intensity) m/z: 479 
(M+, 23.3%). Calcd for C20H17N9O4S (479.47): C, 50.10; 
H, 3.57; N, 26.29; S, 6.69%. Found: C, 50.34; H, 3.28; N, 
26.57; S, 6.41%.
General procedure for the synthesis of compound: 
6-amino-2-(4,6-diamino-1-(2,5-dioxoimidazolidin-4-yl)-
2-oxo-1,2-dihydropyrimidin-5-yl)-4-(4-methoxyphenyl)- 
nicotinonitrile (19)
The solution of compound 17a (0.447 g, 0.001 mol) 
in sodium ethoxide (0.001 mol) [prepared by dissolving 
sodium metal (0.023 g, 0.001 mol) in absolute ethanol (50 
mL)]. The reaction was heated under reflux for 4 h and then 
evaporated under vacuum. The product was triturated with 
ethanol and the formed product was collected by filtration.
Compound 19: Yellow crystals from ethanol, yield 
57%, 0.255 g, m.p. 207-209 ºC. IR (KBr): υ/cm-1 = 3462-
3220 (3NH2, 2NH), 3054 (CH aromatic), 2985 (CH3), 
2766 (CH), 2221 (CN), 1688, 1672, 1664 (3CO), 1655 
(C=N), 1647 (C=C). 1H NMR (DMSO-d6) δ = 3.68 (s, 
3H, OCH3), 4.38, 4.93, 5.33 (3s, 6H, D2O-exchangeable, 
3NH2), 5.77 (s, 1H, imidazolidindione ring), 7.14 (s, 1H, 
pyridine), 7.28-7.49 (d.d, 4H, C6H4), 8.41, 8.82 (2s, 2H, 
D2O-exchangeable, 2NH). 13C NMR: δ = 40.4 (CH3), 
63.3 (CH), 117.8 (CN), 120.6, 123.9, 125.2, 127.6, 131.1, 
133.5, 136.2, 138.4, 140.7, 142.6, 144.5, 145.8 (Pyridine 
C, pyrimidine C, C6H4), 160.8, 163.3, 166.7 (3C=O). 
MS (relative intensity) m/z: 447 (M+, 30.5%). Calcd 
for C20H17N9O4 (447.41): C, 53.69; H, 3.83; N, 28.18%. 
Found: C, 53.44; H, 4.09; N, 28.37%.
General procedure for the synthesis of compounds: 
2-((4,6-diamino -1-(2,5-dioxo- imidazolidin-4-yl) 
-2-oxo -1,2-dihydropyrimidin -5-yl) (imino) methyl) 
-4-hydrazinyl-3-(4-methoxyphenyl)but-2-enenitrile 
(21a) and 2-((4,6-diamino-1-(2,5-dioxo –imidazol- idin-
4-yl)-2-oxo-1,2-dihydropyrimidin-5-yl) (imino) methyl)-
3-(4-methoxy -phenyl)-4-(2-phenyl- hydrazinyl)but-2-
enenitrile (21b) 
Either hydrazine hydrate (20a) (0.1 g, 0.002 mol) 
or phenylhydrazine (20b) (0.22 g, 0.002) was added to a 
solution of compound 15 (1.002 g, 0.002 mol) in ethanol 
(50 mL). The reaction mixture was heated under reflux for 
4 h and then poured onto an ice/water mixture containing a 
few drops of hydrochloric acid. The formed solid product 
was collected by filtration. 
Compound 21a: Pale yellow crystals from ethanol, 
yield 74%, 0.67 g, m.p. 221-223 ºC. IR (KBr): υ/cm-1 
= 3389-3212 (3NH2, 4NH), 3050 (CH aromatic), 2974 
(CH3), 2881 (CH2), 2760 (CH), 2227 (CN), 1683, 
1667, 1660 (3CO), 1655 (C=N), 1649 (C=C). 1H NMR 
(DMSO-d6) δ = 3.19 (s, 3H, OCH3), 3.28 (s, 2H, CH2), 
4.58, 5.12, 5.28 (3s, 6H, D2O-exchangeable, 3NH2), 5.71 
(s, 1H, imidazolidindione ring), 6.83-7.17 (d.d, 4H, C6H4), 
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8.43, 8.68, 8.77, 9.53 (4s, 4H, D2O-exchangeable, 4NH). 
13C NMR: δ = 37.5 (CH3), 53.3 (CH2), 66.7 (CH), 79.4, 
86.4 (C=C), 107.6 (C=N), 115.7 (CN), 120.5, 125.9, 128.2, 
132.3, 134.7, 136.7, 138.9 (pyrimidine C, C6H4), 164.4, 
166.9, 170.2 (3C=O). MS (relative intensity) m/z: 452 
(M+, 27.4%). Calcd for C19H20N10O4 (452,43): C, 50.44; 
H, 4.46; N, 30.96%. Found: C, 50.71; H, 4.73; N, 30.68%.
Compound 21b: Pale yellow crystals from ethanol, 
yield 65%, 0.688 g, m.p. 240-242 ºC. IR (KBr): υ/
cm-1= 3368-3188 (2NH2, 5NH), 3056 (CH aromatic), 
2988 (CH3), 2879 (CH2), 2758 (CH), 2225 (CN), 1688, 
1666, 1661 (3CO), 1657 (C=N), 1650 (C=C). 1H NMR 
(DMSO-d6) δ = 3.12 (s, 3H, OCH3), 3.22 (s, 2H, CH2), 
5.17, 5.44 (2s, 4H, D2O-exchangeable, 2NH2), 5.55 (s, 
1H, imidazolidindione ring), 6.91-7.12 (d.d, 4H, C6H4), 
7.38-7.53 (m, 5H, C6H5), 8.22, 8.51, 8.79, 9.11, 9.58 (5s, 
5H, D2O-exchangeable, 5NH). 13C NMR: δ = 39.4 (CH3), 
51.7 (CH2), 69.5 (CH), 78.8, 83.2 (C=C), 110.4 (C=N), 
117.6 (CN), 120.3, 122.5, 124.7, 127.1, 130.8, 132.6, 
134.8, 136.5, 139.6, 141.2, 143.4, 146.4 (pyrimidine C, 
C6H4, C6H5), 163.3, 165.8, 167.8 (3C=O). MS (relative 
intensity) m/z: 528 (M+, 23.6%). Calcd for C25H24N10O4 
(528.52): C, 56.81; H, 4.58; N, 26.50%. Found: C, 56.55; 
H, 4.33; N, 26.21%.
General procedure for the synthesis of compounds: 
5-(4,6-diamino-5-((1,2-diamino-4-(4-methoxyphenyl)-
1H- pyrrol- 3- yl) (imino)methyl)-2-oxopyrimidin-1(2H)-yl) 
imidazolidine-2,4-dione (23a) and 5-(4,6-diamino-5-
((2-amino-4-(4-methoxyphenyl)-1-(phenylamino)-1H-
pyrrol-3-yl)(imino)methyl)-2-oxopyrimidin-1(2H)-yl)
imidazolidine-2,4-dione (23b) 
The reactions began either with solutions of 
compound 21a (0.452 g, 0.001 mol) or compound 21b 
(0.528 g, 0.001 mol) in sodium ethoxide (0.001 mol) in 
absolute ethanol (50 mL). The reaction was heated under 
reflux for 3 h and then evaporated under vacuum. The 
product was triturated with ethanol and the formed product 
was collected by filtration.
Compound 23a: Creamy white crystals from 
ethanol, yield 57%, 0.258 g, m.p. 178-180 ºC. IR (KBr): 
υ/cm-1 = 3411-3264 (4NH2, 3NH), 3055 (CH aromatic), 
2981 (CH3), 2768 (CH), 1689, 1668, 1663 (3CO), 1651 
(C=N), 1645 (C=C). 1H NMR (DMSO-d6) δ = 3.27 (s, 3H, 
OCH3), 4.38, 4.59, 4.95, 5.23 (4s, 8H, D2O-exchangeable, 
4NH2), 5.63 (s, 1H, imidazolidindione ring), 6.95-7.28 
(m, 4H, C6H4, 1H, pyrrole), 8.51, 8.77, 9.38 (3s, 3H, D2O-
exchangeable, 3NH). 13C NMR: δ = 39.2 (CH3), 64.4 (CH), 
103.8 (C=N), 121.7, 123.6, 126.7, 128.9, 131.4, 133.6, 
136.5, 138.5, 140.2, 143.4, 145.1 (pyrrole C, pyrimidine C, 
C6H4), 167.1, 169.8, 173.4 (3C=O). MS (relative intensity) 
m/z: 452 (M+, 21.5%). Calcd for C19H20N10O4 (452,43): 
C, 50.44; H, 4.46; N, 30.96%. Found: C, 50.18; H, 4.69; 
N, 30.72%.
Compound 23b: Pale yellow crystals from ethanol, 
yield 55%, 0.29 g, m.p. 150-152 ºC. IR (KBr): υ/cm-1= 
3386-3187 (3NH2, 4NH), 3053 (CH aromatic), 2975 
(CH3), 2782 (CH), 1685, 1671, 1665 (3CO), 1656 (C=N), 
1650 (C=C). 1H NMR (DMSO-d6) δ = 3.41 (s, 3H, OCH3), 
4.44, 4.67, 5.21 (3s, 6H, D2O-exchangeable, 3NH2), 5.54 
(s, 1H, imidazolidindione ring), 6.86-7.37 (m, 4H, C6H4, 
5H, C6H5, 1H, pyrrole), 8.43, 8.68, 9.17, 9.56 (4s, 4H, 
D2O-exchangeable, 4NH). 13C NMR: δ = 35.7 (CH3), 57.4 
(CH), 101.4 (C=N), 120.2, 121.9, 123.3, 125.8, 127.5, 
130.1, 132.7, 134.6, 136.7, 139.1, 141.5, 144.1, 146.3, 
147.5 (pyrrole C, pyrimidine C, C6H4, C6H5), 163.3, 
169.4, 171.8 (3C=O). MS (relative intensity) m/z: 528 
(M+, 28.3%). Calcd for C25H24N10O4 (528.52): C, 56.81; 
H, 4.58; N, 26.50%. Found: C, 56.55; H, 4.86; N, 26.33%.
General procedure for the synthesis of compounds: 
5-(4-amino-6-imino-2-oxo-5-(1-phenylethylidene)-5,6-
dihydropyrimidin-1(2H)-yl)imidazolidine-2,4-diones 
(25a), 5-(4-amino-6-imino-2-oxo-5-(2-phenylhydrazono-
5,6-dihydropyrimidin-1(2H)-yl) imidazol- idine-2,4-
dione (25b) and 5-(4-amino-5-(2-(4-chlorophenyl)
hydrazono)-6-imino-2-oxo-5,6-dihydro- pyrimidin-1(2H)-
yl)imidazolidine-2,4-dione (25c)
Either compound 24a (0.505 g, 0.003 mol), 24b 
(0.614 g, 0.003 mol) or 24c (0.474 g, 0.003 mol) was added 
to a solution of 5-ureidohydantion (2) (0.474 g, 0.003 mol) 
in 50 mL of ethanol containing dimethylformamide 
(5.0 mL) and triethylamine (1.0 mL) as a catalyst. The 
reaction mixture was heated under reflux for 5 h, cooled 
and poured onto ice containing a few drops of HCl. The 
formed solid product was filtered out.
Compound 25a :  Pale brown crystals  from 
ethanol, yield 61%, 0.597 g, m.p. 251-253 ºC. IR (KBr): 
υ/cm-1= 3407-3326 (NH2, 3NH), 3051 (CH aromatic), 
2978 (CH3), 2734 (CH), 1688, 1671, 1662 (3CO), 1657 
(C=N), 1647 (C=C). 1HNMR (DMSO) δ = 1.87 (s, 3H, 
CH3), 4.63 (s, 2H, D2O-exchangeable, NH2), 5.65 (s, 1H, 
imidazolidindione ring), 7.27-7.44 (m, 5H, C6H5), 8.22, 
8.46, 9.37 (3s, 3H, D2O-exchangeable, 3NH). 13C NMR: 
δ = 23.3 (CH3), 61.4 (CH), 86.4 (C=C), 118.7, 123.5, 
126.7, 128.9, 130.2, 133.6, 137.4, 139.3 (pyrimidine C, 
C6H5), 160.2, 162.7, 165.6 (3C=O). MS (relative intensity) 
m/z: 326 (M+, 19.8%). Calcd for C15H14N6O3 (326.31): C, 
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55.21; H, 4.32; N, 25.75%. Found: C, 55.48; H, 4.05; N, 
25.49%.
Compound 25b: Brown crystals from ethanol, 
yield 53%, 0.522 g, m.p. 197-199 ºC. IR (KBr): 
υ/cm-1 = 3428-3335 (NH2, 4NH), 3053 (CH aromatic), 2766 
(CH), 1684, 1672, 1664 (3CO), 1656 (C=N), 1649 (C=C). 
1HNMR (DMSO) δ = 4.55 (s, 2H, D2O-exchangeable, NH2), 
5.43 (s, 1H, imidazolidindione ring), 7.18-7.37 (m, 5H, 
C6H5), 8.33, 8.49, 8.74, 9.37 (4s, 4H, D2O-exchangeable, 
4NH). 13C NMR: δ = 65.5 (CH), 120.4, 122.7, 125.9, 127.4, 
130.4, 132.8, 135.8, 138.7 (pyrimidine C, C6H5), 161.7, 
163.9, 165.5 (3C=O). MS (relative intensity) m/z: 328 (M+, 
15.7%). Calcd for C13H12N8O3 (328.29): C, 47.56; H, 3.68; 
N, 34.13%. Found: C, 47.31; H, 3.94; N, 34.37%.
Compound 25c: Brown crystals from ethanol, yield 
57%, 0.62 g, m.p. 218-220 ºC. IR (KBr): υ/cm-1= 3444-
3352 (NH2, 4NH), 3057 (CH aromatic), 2761 (CH), 1682, 
1670, 1663 (3CO), 1653 (C=N), 1647 (C=C). 1HNMR 
(DMSO) δ = 4.72 (s, 2H, D2O-exchangeable, NH2), 5.66 
(s, 1H, imidazolidindione ring), 7.39-7.54 (d.d, 4H, C6H4), 
8.38, 8.62, 8.88, 9.28 (4s, 4H, D2O-exchangeable, 4NH). 
13C NMR: δ = 54.8 (CH), 121.4, 123.6, 125.7, 128.5, 
131.5, 133.9, 135.7, 139.5 (pyrimidine C, C6H4), 162.8, 
164.7, 167.3 (3C=O). MS (relative intensity) m/z: 362 
(M+, 15.7%). Calcd for C13H11ClN8O3 (362.73): C, 43.05; 
H, 3.06; N, 30.89%. Found: C, 43.33; H, 3.34; N, 30.62%.
Pharmacology
Analgesic activity
 Analgesic activity was introduced by the tail flick 
method (Fadeyi et al., 2004; Vogel, 2002). Healthy albino 
mice weighing 20.0 g to 30.0 g were divided into different 
groups with six animals in each group. The control group 
received a 0.5% w/v carboxymethylcellulose (CMC) 
solution and the treated groups were given a 132 µmol/kg 
orally dose of compounds 3, 7, 9a ,b, 11, 13a ,b, 15, 17a, 
b, 19, 21a, b, 23a, b and 25a, b, c. The reaction times were 
noted at 2 h and 4 h intervals after drug administration. 
The percentage analgesic activity was calculated by the 
following formula:-
Percentage analgesic activity = T2-T1/T1×100
where:- T1 is the normal reaction time; T2 is the reaction 
time after treatment.
Antipyretic activity
Healthy Wistar rats were given s.c. 10mL/kg of 
a 20% aqueous suspension of sterilized brewer’s yeast 
powder (Fadeyi et al., 2004; Vogel, 2002) weighting 
between 150 g and 200 g. Eighteen hours later, the animals 
showing an increase in rectal temperature greater than 0.5 
ºC were selected. The control group received a 0.5% w/v 
carboxymethylcellulose solution and the treated groups 
received a of 132 µmol/kg dose of compounds 3, 7, 9a, 
b, 11, 13a, b, 15, 17a, b, 19, 21a, b, 23a, b and 25a, b, c. 
Rectal temperatures were noted using digital thermometer 
30 minute before (pretreated) and at 1 h, 2 h and 4 h after 
administration of the dose.
Anti-inflammatory activity
 
The anti-inflammatory activity was examined using 
a hind paw edema method on albino rats of either six 
(Fadeyi et al., 2004; Vogel, 2002). A freshly prepared of 
carrageenan solution (0.1mL, 1%w/v) was injected into the 
sub-plantar surface of the right hind limb of each animal. 
The control group received a 0.5% w/v CMC solution and 
the treated groups were orally given a 132 µmol/kg dose 
of compounds 3, 7, 9a ,b, 11, 13a ,b, 15, 17a, b, 19, 21a, 
b, 23a, b and 25a, b, c 30 minute before carrageenan. The 
volume of each paw was measured with a plethysmometer 
at 2 h and 4 h intervals after carrageenan injection. The 
percentage inhibition of edema was calculated by the 
following formula: 
Percentage inhibition of edema: VC-VT/VC×100
where: VC is the paw volume of control animal; VT is the 
paw volume of treated animals (standard /test compound).
RESULTS AND DISCUSSION
This study was a continuation of our efforts 
aimed at the synthesis of new heterocyclic compounds 
with significant biological potential (El-Sharkawy et 
al., 2012; Mohareb, El-Sharkawy, Sherif, 2008). The 
goals of this work were to study the possibility of using 
compounds 2 and 3 in heterocyclic synthesis to produce 
the pyridopyrimidine derivative 7; thiophene derivatives 
9a,b; coumarin derivative 11; pyrimidine derivatives 
13,15,17a,b,21a,b; pyridine derivative 19; pyrazole 
derivatives 23a,b and iminopyrimidine derivatives 
25a,b,c, as well as biologically evaluate these compounds 
for analgesic, antipyretic and anti-inflammatory activities. 
The reaction of β-amino-α, γ-dicyanocrotono- nitrile (1) 
with 5-ureidohydantion (2) using triethylamine as catalyst 
produced compound 3. The latter product underwent 
cyclization in the presence of piperidine. Four isomeric 
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structures were considered, including 4,5,6 and 7. The 
1HNMR spectral data showed that the final product 
contained three singlets at δ = 4.78, 4.93, 5.27 ppm and 
two singlets at δ = 8.73, 9.95 ppm which represented the 
presence of 3NH2 and 2NH groups, respectively; thus, 
the structures of compounds 4,5 and 6 were ruled out, 
as those latter structures only containing 2NH2 groups. 
Additionally, structure 6 contained an OH group which it 
was absent in the analytical and spectral data. In contrast, 
compound 7 was produced by another pathway, through 
the reaction of β-amino-α, γ-dicyanocrotononitrile (1) with 
5-ureidohydantion (2) in the presence of sodium ethoxide 
directly. Compound 3 reacted with either cyclopentanone 
(8a) or cyclohexanone (8b) in the presence of elemental 
sulfur and trimethylamine afforded compounds 9a,b 
respectively. The structures of compounds 9a,b were 
verified by elemental analysis and spectral data. In 
compound 9a, the 1HNMR spectrum indicated the 
presence of a multiplet at δ = 2.07-2.18 ppm which could 
be assigned to the 3CH2 groups; three singlets at δ = 4.54, 
4.65, 5.81 ppm, which indicate the presence of 3NH2 
groups; a singlet at δ = 5.98 ppm, which indicate the 
presence of 1H of an imidazolidindione ring and three 
singlets at δ = 8.52, 8.77, 9.12 ppm corresponding to 
3NH groups. Coumarin derivative 11 was formed via the 
reaction of compound 3 with salicylaldehyde (10) and the 
structure of the compound was confirmed. The 1HNMR 
spectrum indicated the presence of two singlets at δ = 4.76, 
5.25 ppm, which indicate the presence of 2NH2 groups; a 
singlet at δ = 5.53 ppm, which indicates the presence of an 
1H of imidazolidindione ring; a singlet at δ = 6.73 ppm, 
which indicate the presence of a coumarin 1H; a multiplet 
at δ = 7.51-7.66 ppm corresponding to 4H of benzene 
ring; and three singlets at δ = 8.88, 9.28, 9.55 ppm, 
which indicate the presence of 3NH groups. Compound 
3 was also reacted with aryldiazonium salts 12a,b to 
afford arylhydrazono derivatives 13a,b respectively. The 
elucidation of the structure for these compounds was then 
FIGURE 1 - Synthesis rout for compounds 3 and 7.
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confirmed. The 1HNMR spectrum for compound 13a 
showed the presence of two singlets at δ = 4.54, 5.17 ppm, 
which indicate the presence of 2NH2 groups; a singlet at 
δ = 5.61 ppm, which indicates the presence of 1H of an 
imidazolidindione ring; a multiplet at δ = 7.31-7.62 ppm 
corresponding to 5H of benzene ring; and four singlets at 
δ = 8.76, 9.13, 9.38, 959 ppm which indicate the presence 
of 4NH groups. 
The last reaction of compound 3, was performed 
with ω-bromo-4-methoxyacetophenone (14), and the 
4-methoxyphenylbutenyl derivative 15 was afforded. 
The elucidation of this structure was based on analytical 
and spectral data. Compound 15 was reacted with either 
potassium cyanide (16a) or potassium thiocyanate (16b) 
to form either the 4-methoxyphenylbutenyl cyanide 
derivative 17a or 4-methoxyphenylbutenyl thiocyanide 
derivative 17b, respectively. The structures of compounds 
17a,b were verified by analytical and spectral data. 
Compound 17a underwent a cyclization in presence of 
sodium ethoxide to afford pyridine derivative 19 via 
formation of intermediate 18. The structure of compound 
19 was then confirmed. The 1HNMR spectrum of 
compound 19 detected the presence of singlet at δ = 3.68 
ppm, which indicates the presence of 3H of CH3 group; 
three singlets at δ = 4.38, 4.93 5.33 ppm, which indicate the 
presence of 3NH2 groups; a singlet at δ = 5.77 ppm, which 
indicates the presence of 1H of imidazolidindione ring; a 
singlet at δ = 7.14 ppm which indicates the presence of 
1H of pyridine ring; a doublet of doublets at δ = 7.28-7.49 
ppm corresponding to 4H of benzene ring and two singlets 
at δ = 8.41, 8.82 ppm, which indicate the presence of 2NH 
groups. Compound 15 was reacted with either hydrazine 
hydrate (20a) or phenyl hydrazine (20b) to produce 
hydrazono derivatives 21a,b, respectively. The structures 
of these compounds were confirmed by analytical and 
spectral data. The latter products underwent a cyclization 
to form pyrrole derivatives 23a,b through the intermediate 
formation of 22a,b, respectively. The structures of 
compounds 23a,b were confirmed using analytical and 
spectral data. The 1HNMR spectrum of compound 23a 
FIGURE 2 - Synthesis rout for compounds 9a,b, 11, 13a,b and 15.
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FIGURE 3 - Synthesis rout for compounds 17a,b, 19 and 21a,b.
FIGURE 4 - Synthesis rout for compounds 23a,b and 25a,b,c.
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detected the presence of a singlet at δ = 3.27 ppm, which 
indicates the presence of 3H from a CH3 group; four 
singlets at δ = 4.38, 4.59, 4.95, 5.23 ppm, which indicate 
the presence of 4NH2 groups; a singlet at δ = 5.63 ppm, 
which indicates the presence of 1H of imidazolidindione 
ring; a multiplet at δ = 6.95-7.28 ppm corresponding to 4H 
of benzene ring and 1H of pyrrole ring and three singlets 
at δ = 8.51, 8.77, 9.38 ppm, which indicate the presence 
of 3NH groups. Finally 5-ureidohydantion (2) was reacted 
with compounds 24a,b,c to produce iminopyrimidine 
derivatives 25a,b,c, respectively and the structure of these 
compounds were confirmed by analytical and spectral 
data. 
All the synthesized compounds were evaluated for 
their in vitro analgesic, antipyretic and anti-inflammatory 
activities. Acetaminophen was used as a reference 
TABLE I - Analgesic activities of the synthesized compounds
Comp. No Normal reaction time (sec)
Change in reaction time (sec) ± SEM % Analgesic activity ± SD
2 h 4 h 2 h 4 h
Control 2.80±0.15 0.20±0.014 0.25±0.018 7.09±1.45 9.05±0.87
3 2.20±0.09 3.21±0.15 2.25±0.08 113.1±1.57 89.76±2.23
7 2.35±0.08 3.24±0.10 2.35±0.07 115.4±1.38 94.53±0.44**
9a 2.60±0.07 3.20±0.08 2.33±0.06 129.1±1.65 95.24±1.53**
9b 2.57±0.07 3.17±0.09 2.36±0.05 131.3±1.58 92.56±1.38**
11 2.38±0.08 3.18±0.08 2.43±0.03 125.1±1.68 97.56±0.55***
13a 2.56±0.06 3.22±0.11 2.38±0.04 133.6±1.76 95.84±2.05**
13b 2.48±0.06 3.21±0.08 2.29±0.07 136.4±1.48 94.11±0.43**
15 2.53±0.08 3.32±0.15 2.42±0.08 140.5±1.54 84.82±1.23
17a 2.16±0.07 3.33±0.19 1.96±0.05 145.6±1.64 86.52±1.18
17b 2.36±0.12 3.48±0.12 2.21±0.03 138.8±1.98 89.33±2.66
19 2.20±0.11 3.15±0.07 2.40±0.06 119.5±1.45 96.5±0.25***
21a 2.25±0.09 3.44±0.13 2.25±0.08 147.1±1.77 90.5±1.46
21b 3.15±0.06 3.38±0.14 2.05±0.07 144.3±1.48 103.55±1.53
23a 2.60±0.12 3.47±0.18 1.98±0.07 141.1±1.88 92.4±2.36*
23b 2.50±0.12 3.31±0.13 1.96±0.06 112.3±1.93 90.9±0.95*
25a 2.75±0.09 3.34±0.16 2.15±0.08 117.3±1.73 89.5±1.65
25b 2.80±0.08 3.38±0.17 2.22±0.05 113.1±2.00 104.2±2.44
25c 2.65±0.06 3.39±0.15 2.18±0.06 108.3±1.43 88.7±2.98
Ref. Standard 
(Acetaminophen)
2.50±0.10 3.10±0.05 2.5±0.03 128.6±1.75 103.6±1.58***
Note: The reaction time value is the mean ± SEM (n=6). Statistical analysis was performed with the student’s unpaired t-test 
(Kulkarni, 2003). *p < 0.05, **p < 0.01 and ***p < 0.001, 132 µmol/kg dose.
standard drug. Based on the results from (Tables I 
and II), it is clear that compounds 11 and 19 showed 
promising actions as analgesic and antipyretic agents. 
This may be due their containing a coumarin moiety and 
4-methoxyphenylpyridine moiety, respectively. In contrast, 
compounds 7, 9a, b, 13a, b showed moderate analgesic 
and antipyretic effects. The remaining compounds 3, 
15, 17a, b, 21a, b, 23a, b, 25a, b, c exhibited poor 
analgesic and antipyretic effects. Compound 11 exhibited 
high significance as an anti-inflammatory agent, which 
may be due to the presence of the coumarin moiety. 
Compounds 7, 9b, 13b, 19 were considered as moderate 
anti-inflammatory effects. The remaining compounds 3, 
9a, 13a, 15, 17a, b, 21a, b, 23a, b, 25a, b, c exhibited 
poor biological significance as anti-inflammatory agents 
(Table III).
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TABLE II - Antipyretic activities of the synthesized compounds 
Comp. No
Before drug (ºC) After drug (oC)
-18 h 0.0 h 1 h 2 h 4 h
Control 37.47±5.68 38.22±0.05 38.08±0.08 38.04±0.05 37.83±0.5
3 37.35±0.05 38.17±0.75 37.88±0.07 37.58±0.08 37.33±0.05
7 37.41±0.05 38.38±0.05 38.12±0.05 37.55±0.06 37.28±0.05**
9a 37.36±0.04 38.33±0.06 37.95±0.08 37.65±0.07 37.32±0.05**
9b 37.32±0.05 38.35±0.06 38.14±0.07 37.54±0.08 37.26±0.05**
11 37.23±0.09 38.40±0.08 37.93±0.06 37.63±0.05 37.44±0.06***
13a 37.40±0.05 38.37±0.05 38.25±0.08 37.55±0.06 37.31±0.05**
13b 37.44±0.06 38.39±0.05 37.98±0.06 37.38±0.08 37.27±0.05**
15 37.36±0.06 38.34±0.05 38.08±0.07 37.88±0.06 37.45±0.05
17a 37.34±0.06 38.37±0.08 38.05±0.08 37.68±0.07 37.39±0.03
17b 37.44±0.05 38.39±0.08 38.18±0.06 37.91±0.05 37.58±0.07
19 37.28±0.04 38.31±0.07 38.05±0.07 37.60±0.05 37.37±0.04***
21a 37.30±0.06 38.27±0.35 37.95±0.08 37.58±0.07 37.31±0.05
21b 37.43±0.08 38.41±0.45 38.12±0.07 37.74±0.08 37.47±0.02
23a 37.39±0.08 38.44±0.53 38.19±0.08 37.87±0.05 37.55±0.04*
23b 37.31±0.07 38.39±0.06 38.10±0.07 37.64±0.05 37.42±0.07*
25a 37.29±0.06 38.32±0.07 38.04±0.07 37.34±0.09 37.18±0.09
25b 37.35±0.05 38.38±0.07 37.85±0.08 37.85±0.06 37.46±0.09
25c 37.44±0.08 38.44±0.35 37.92±0.07 37.92±0.05 37.42±0.08
Ref. Standard 
(Acetaminophen)
37.18±0.07 37.88±0.05 37.72±0.04 37.41±0.04 37.20±0.05***
Note: The reaction time value is the mean ± SEM (n=6). Statistical analysis was performed with student’s unpaired t-test (Kulkarni, 
2003). *p < 0.05, **p < 0.01 and *** p < 0.001, 132 µmol/kg dose.
CONCLUSIONS
In this article, the synthesized pyrimidines 
3, 7, 13a,b, 15, 17a,b, 21a,b, 25a, b, c; thiophenes 
9a, b; coumarin 11, pyridine 19 and pyrroles 23a, 
b were evaluated as analgesic, antipyretic and anti-
inflammatory agents compared to the reference standard 
drug acetaminophen. Among the newly synthesized 
compounds, compounds 11 and 19 showed promising 
significant analgesic and antipyretic activities compared 
to the other compounds. Additionally compounds 7, 
9a,b and 13a,b had moderately significant analgesic and 
antipyretic activities. Moreover, compound 11 had clear 
anti-inflammatory properties compared to the remaining 
compounds.
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TABLE III - Anti-inflammatory activities of the synthesized compounds 
Comp. No
Change in reaction time (sec)±SEM % Anti-inflammatory activity±SD
2 h 4 h 2 h 4 h
Control 1.29±0.01 1.32±0.007
3 0.83±0.01 0.80±0.01 34.56±3.38 35.78±3.52
7 0.82±0.02 0.83±0.01 31.34±2.87 33.59±2.26**
9a 0.82±0.01 0.85±0.01 32.44±2.55 34.23±2.68
9b 0.81±0.03 0.82±0.01 31.12±3.51 34.19±3.07**
11 0.82±0.02 0.84±0.01 29.34±2.97 32.08±2.05***
13a 0.81±0.01 0.85±0.01 32.56±3.08 33.38±3.17
13b 0.83±0.03 0.84±0.01 32.34±2.26 35.27±2.02**
15 0.84±0.02 0.81±0.01 27.88±2.66 32.17±1.87
17a 0.83±0.02 0.86±0.01 34.23±3.44 37.18±3.25
17b 0.86±0.01 0.87±0.01 35.56±3.14 36.34±1.48
19 0.81±0.01 0.83±0.01 30.34±3.24 34.03±2.53**
21a 0.83±0.03 0.85±0.01 26.23±2.57 29.28±1.38
21b 0.85±0.01 0.81±0.01 35.39±3.28 37.31±1.93
23a 0.84±0.02 0.88±0.01 34.18±2.73 35.98±3.02
23b 0.78±0.02 0.82±0.01 33.85±3.27 35.58±2.17
25a 0.83±0.02 0.80±0.01 33.37±3.26 36.18±1.59
25b 0.79±0.01 0.83±0.01 32.94±2.62 35.42±3.46
25c 0.83±0.03 0.87±0.01 34.23±3.17 36.14±1.83
Ref. Standard 
(Acetaminophen)
0.83±0.01 0.84±0.01 28.83±3.05 32.82±1.33***
Note: The reaction time value is the mean ± SEM (n=6). Statistical analysis was performed with student’s unpaired t-test (Kulkarni, 
2003). *p < 0.05, **p < 0.01 and *** p < 0.001, 132 µmol/kg dose.
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